Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

William G. Wierda, Matthew S. Davids, Jeff P. Sharman, Nilanjan Ghosh, Yang Feng, Mary Jean Fusco, Jacqueline Hilger-Rolfe, Chen Qian, Wendy J. Sinai, Sophie Wimberley, John F. Seymour

Blood (2024) 144 (Supplement 1): 6784.

https://doi.org/10.1182/blood-2024-207716

Published: 2024

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Blood (2024) 144 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2024-200958

Published: 2024

Journal Articles

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Manali Kamdar, David G. Maloney, Mazyar Shadman, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Juliana E. Hidalgo-López, Jing Wang, Ken Ogasawara, Ashvin Singh, Tanya Siddiqi

Blood (2024) 144 (Supplement 1): 3125.

https://doi.org/10.1182/blood-2024-200204

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma

David M Foureau, Fei Guo, Erik Broemsen, Tahj Jones, Anna Ivanina-Foureau, Ryan Jacobs, Bei Hu, Tamara K Moyo, Yifan Pang, Steven I. Park, Lawrence J. Druhan, Ariel Bell, Nilanjan Ghosh

Blood (2024) 144 (Supplement 1): 2053.

https://doi.org/10.1182/blood-2024-205720

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 989.

https://doi.org/10.1182/blood-2024-194581

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Representation of Minorities in Therapeutic Clinical Trials - a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)

Alvaro J Alencar, Susan M. Geyer, Electra D Paskett, Levi D. Pederson, Travis Dockter, Nilanjan Ghosh, Kehinde Adekola, Joseph M Unger, Opeyemi Jegede, Jonathan W. Friedberg, Brad S. Kahl, Shira N. Dinner, Nancy L. Bartlett, Kristie A. Blum, John P. Leonard

Blood (2024) 144 (Supplement 1): 110.

https://doi.org/10.1182/blood-2024-209365

Published: 2024

Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Blood (2024) 144 (Supplement 1): 4625.

https://doi.org/10.1182/blood-2024-205223

Published: 2024

Journal Articles

Communicating with Patients While Navigating the New Landscape of Diffuse Large B-Cell Lymphoma (DLBCL)

Lilly Meier, Elizabeth Budde, Liffy Indu Cherian, Matthew Matasar, Amitkumar Mehta, Nilanjan Ghosh, Ashley Lile, Elana Plotkin, Nicole A Colwell, Molly Kisiel

Blood (2024) 144 (Supplement 1): 7945.

https://doi.org/10.1182/blood-2024-194129

Published: 2024

Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi

Blood (2024) 143 (5): 404–416.

https://doi.org/10.1182/blood.2023020854

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Michael Wang, Wojciech Jurczak, Marek Trněný, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Edith Szafer Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam

Blood (2023) 142 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2023-191921

Published: 2023

Journal Articles

Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study

Nilanjan Ghosh, Ruibin Wang, Zhijie Ding, Jinghua He, Alex Bokun, Heena Mavani, Zaina P Qureshi, Kerry A Rogers

Blood (2023) 142 (Supplement 1): 270.

https://doi.org/10.1182/blood-2023-187743

Published: 2023

Journal Articles

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

Nilanjan Ghosh, Zaina P Qureshi, Zhijie Ding, Marie-Helene Lafeuille, Bruno Emond, Priyanka Gogna, Bronwyn Moore, Patrick Lefebvre, Alex Bokun, Heena Mavani, Kerry A Rogers

Blood (2023) 142 (Supplement 1): 1915.

https://doi.org/10.1182/blood-2023-186284

Published: 2023

Journal Articles

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2023-182747

Published: 2023

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Maria Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew A Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2023-178109

Published: 2023

Journal Articles

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Anita Kumar, Ashlee Joseph, Brian T. Hill, Taylor R. Brooks, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine McCarthy, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Philip Young, Craig A. Portell, Zoey I. Harris, Javier L. Munoz, Patrick M. Reagan, Georgio Pongas, Izidore S. Lossos, Christine E. Ryan, Reid W. Merryman, Firas Baidoun, Muhamad Alhaj Moustafa, Drew Gerber, Sabarish R. Ayyappan, Brian K. Link, Arash Velayati, Irl Brian Greenwell, Lauren G Banaszak, Priyanka A Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur Narkhede, Amitkumar N. Mehta, Preetesh Jain, Michael L. Wang, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Laveniya Kugathasan, Diego Villa, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Blood (2023) 142 (Supplement 1): 300.

https://doi.org/10.1182/blood-2023-182942

Published: 2023

Journal Articles

Myeloid Derived Suppressor Cell Kinetics in Peripheral Blood Correlate with Efficacy and Toxicity of CAR T Cell Therapy in Relapsed or Refractory B Cell Lymphoma

David M Foureau, Hamid Ehsan, Fei Guo, Tahj Jones, Ryan W Jacobs, Bei Hu, Tamara K. Moyo, Yifan Pang, Steven I. Park, Lawrence J. Druhan, Ariel Bell, Nilanjan Ghosh

Blood (2023) 142 (Supplement 1): 1640.

https://doi.org/10.1182/blood-2023-187085

Published: 2023

Journal Articles

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Michael L. Wang, Sarit Assouline, Manali Kamdar, Nilanjan Ghosh, Seema Naik, Shazia K. Nakhoda, Julio C. Chavez, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Wahib Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 734.

https://doi.org/10.1182/blood-2023-174956

Published: 2023

NARROW

Venetian: A Phase 2b/3 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) and Optimize Initiation of Venetoclax (Ven) in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

CAR-T Cell Subsets and Immune Repertoire Are Associated with Immune-Related Adverse Events and Efficacy after CD19 CAR T-Cell Therapy in B Cell Lymphoma

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Representation of Minorities in Therapeutic Clinical Trials - a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Communicating with Patients While Navigating the New Landscape of Diffuse Large B-Cell Lymphoma (DLBCL)

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study

Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study

Ibrutinib Dose Adjustment Does Not Impact Time to Next Treatment in First-Line Patients with Chronic Lymphocytic Leukemia: A Real-World Analysis of Electronic Medical Records from Academic and Non-Teaching Hospitals Using Target Trial Emulation

An International Multicohort Study of Conditional Survival and Cause of Death after Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy

Myeloid Derived Suppressor Cell Kinetics in Peripheral Blood Correlate with Efficacy and Toxicity of CAR T Cell Therapy in Relapsed or Refractory B Cell Lymphoma

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only